A newly approved heart failure drug that was fast-tracked by the FDA is the first in its class.
The FDA approved Amgen’s Corlanor in mid-April for certain patients with left ventricular heart failure. It is indicated for patients with stable symptoms and a normal heartbeat with a resting heart rate of at least 70 beats per minute who also take the highest dose of β-blockers they can tolerate.
In a clinical trial including 6505 patients, Corlanor reduced the risk of hospitalization for worsening heart failure compared with placebo. The most common adverse effects in the clinical trial were bradycardia, hypertension, atrial fibrillation, and temporary vision disturbances.
Rubin R. New Type of Drug for Heart Failure. JAMA. 2015;313(19):1898. doi:10.1001/jama.2015.4799